Ticker

License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease License of the MIT patent strengthens Rafael's intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's Disease

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) and Rafael (NYSE: RFL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Profitability This table compares Elite Pharmaceuticals and Rafael's

Transaction creates global coffee powerhouse  Oliveira will continue as JDE Peet's CEO and joins KDP to lead combined coffee business This is a joint press release by Keurig Dr Pepper Inc., Kodiak BidCo B.V. and JDE Peet's N.V.

Transaction creates global coffee powerhouse Oliveira will continue as JDE Peet's CEO and joins KDP to lead combined coffee business This is a joint press release by Keurig Dr Pepper Inc., Kodiak BidCo B.V. and JDE Peet's N.V.

NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026.